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Abstract: The botulinum neurotoxins (BoNTs) exhibit zinc-dependent proteolytic activity 
against members of the core synaptic membrane fusion complex, preventing neurotransmitter 
release and resulting in neuromuscular paralysis. No pharmacologic therapies have been 
identified  that  clinically  relieve  botulinum  poisoning.  The  black  widow  spider  venom  
α-latrotoxin (LTX) has the potential to attenuate the severity or duration of BoNT-induced 
paralysis  in  neurons  via  the  induction  of  synaptic  degeneration  and  remodeling.  The 
potential for LTX to antagonize botulinum poisoning was evaluated in embryonic stem 
cell-derived neurons (ESNs), using a novel screening assay designed around the kinetics of 
BoNT/A activation. Exposure of ESNs to 400 pM LTX for 6.5 or 13 min resulted in the 
nearly complete restoration of uncleaved SNAP-25 within 48 h, whereas treatment with 
60 mM K
+ had no effect. Time-lapse imaging demonstrated that LTX treatment caused a 
profound increase in Ca
2+ influx and evidence of excitotoxicity, though ESNs remained 
viable 48 h after LTX treatment. This is the first instance of a cell-based treatment that has 
shown the ability to eliminate BoNT activity. These data suggest that LTX treatment may 
provide the basis for a new class of therapeutic approach to BoNT intoxication and may 
contribute to an improved understanding of long-term mechanisms of BoNT intoxication 
and recovery. They further demonstrate that ESNs are a novel, responsive and biologically 
relevant model for LTX research and BoNT therapeutic drug discovery. 
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1. Introduction 
The Clostridium botulinum neurotoxins (BoNTs) are the most poisonous substances known, with 
human toxicities estimated to be as low as 1–2 ng/kg [1]. Following ingestion, inhalation or injection, 
BoNTs gain access to the presynaptic termini of neuromuscular junctions and specifically target the 
soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins VAMP-2, 
SNAP-25, or syntaxin-1 for proteolysis [2]. In the standard model of synaptic neurotransmission, the 
arrival  of  an  action  potential  (AP)  at  the  presynaptic  compartment  triggers  Ca
2+  influx  through  
voltage-gated  channels,  which  in  turn  induces  the  synaptic  SNARE  complex  to  mediate  synaptic 
vesicle fusion and neurotransmitter release. Consequently, BoNT cleavage of these proteins leads to 
inhibition of synaptic exocytosis and resulting in skeletal muscle paralysis with emergent respiratory 
failure  [1].  Although  passive  immunotherapy  can  reduce  vascular  toxin  load,  once  the  toxin  is 
sequestered within the presynaptic terminus there are currently no therapeutic approaches that restore 
normal  synaptic  activity.  Interference  with  toxin  internalization  or  activation  involves  a  short 
therapeutic window; delays the onset of paralysis but  does not prevent intoxication; and does not 
appear to add significant clinical value to the current post-exposure prophylaxis offered by passive 
immunizations [3,4]. Thus, once evidence of intoxication is present, clinical options are largely limited 
to supportive care [5]. Depending on the BoNT serotype, paralysis can persist for months, requiring 
sustained  intensive  medical  care  [6].  Furthermore,  once  the  toxin  is  cleared  from  poisoned  nerve 
termini, the synapse must be regenerated and coordinated neuromuscular control re-established [7–9]. 
For  these  reasons,  the  BoNTs  present  potent  health  risks,  and  in  recognition  of  their  disruptive 
potential the neurotoxins have been designated as one of six CDC Category A bioterrorism agents.  
The neurotoxin α-latrotoxin (LTX) is a highly potent secretagogue derived from the venom of the 
black widow spider (Latrodectus mactans tredecimguttatus) that induces fulminant neurotransmitter 
release at central and autonomic synapses [10–12]. In the most direct method of action, LTX inserts 
into the membrane following binding to the cell surface proteins neurexin or latrophilin and forms 
homotetramers with a central,  non-selective cation-conducting pore [10,13–15]. The resultant influx  
of Ca
2+ into the synaptic terminal induces sustained synaptic exocytosis, mimicking the activation of 
voltage-dependent Ca
2+ channels during an AP. Surprisingly, this mechanism supports high levels of 
neurotransmitter release even in the absence of SNAP-25, synaptobrevin-2 or Munc13-1, which under 
normal circumstances nearly eliminates Ca
2+-evoked
 vesicle fusion [16–19]. LTX treatment caused a 
rapid, prolonged release of large amounts of neurotransmitter, followed by dose-dependent changes in 
nerve terminal morphology, presumably as a consequence of excitotoxicity [20–23]. In vivo, treatment of 
neuromuscular  junctions  with  a  crude  homogenate  from  black  widow  spider  glands  results  
in structural and functional degeneration in hours, followed by regeneration of neuromuscular junctions 
and  resumption  of  synaptic  transmission  at  the  original  endplate  within  days  [23,24].  Treatment  of 
BoNT/A-intoxicated  extensor  digitalis  longus  (EDL)  neuromuscular  junctions  with  the  same  crude 
preparation shortened paralysis from weeks to days [25]. Similarly, recovery from BoNT intoxication Toxins 2011, 3                                       
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can also be expedited by nerve crush treatment [26,27]. Together, these findings suggest that the use of 
chemical or physiological treatments that induce synaptic regeneration of remodeling may accelerate the 
recovery of nerve terminals from BoNT paralysis.  
We  have  previously  described  a  method  to  generate  effectively  pure  cultures  of  glutamatergic 
neurons (ESNs) from suspension-cultured embryonic stem (ES) cells within 8 days, with typical yields 
of approximately 7 ×  10
8 glutamatergic neurons from 4 ×  10
6 mES cells [28]. ESNs express and 
correctly localize neuron-specific proteins, form synapses and release glutamate in a calcium-dependent 
manner under depolarizing conditions. The BoNT substrate SNARE proteins are expressed within 5 d 
of plating, and treatment with 0.81 pM BoNT/A holotoxin results in proteolysis of 50% of cellular 
SNAP-25 within 24 h. This sensitivity to BoNT/A is within two-fold of that observed in primary spinal 
cord neurons after 48 h of exposure, suggesting that botulinum is internalized, processed and behaves 
similarly in the two cell models [29]. In this effort, we developed ESNs as a therapeutic research 
platform, hypothesizing that LTX activity in the presynaptic compartment has potential as a research 
tool and a novel therapeutic approach for botulinum intoxication. We report that ESNs are responsive 
to  the  acute  and  long-term  consequences  of  LTX  treatment;  in  vivo  reports  of  accelerated  nerve 
terminal  regeneration  following  administration  of  crude  gland  homogenates  could  be  attributed 
specifically  to  LTX  activity;  and  LTX  treatment  results  in  the  recovery  of  full-length  SNAP-25  
within 48 h. 
2. Materials and Methods 
2.1. Reagents 
Botulinum holotoxin type A (BoNT/A)  (Metabiologics, Madison, WI, USA) was  resuspended in 
phosphate buffered saline, pH 7.4 to 1 mg/mL, and stored at −20 ° C. Latrotoxin (Sigma-Aldrich, St. 
Louis,  MO,  USA)  was  resuspended  to  300  nM  in  H2O  and  stored  at  −20  ° C.  Fluo-4  (Invitrogen, 
Carlsbad, CA, USA) and Calcein/AM (Invitrogen) were prepared per the manufacturer‘s instructions. 
During time-lapse imaging neurons were maintained in basal electrophysiologic buffer (BEB; 10 mM 
glucose, 1 mM MgCl2, 10 mM HEPES, 2 mM CaCl2, 3 mM KCl, 136 NaCl and 0.1% BSA, pH 7.4,  
310 ±  10 mOsm). High potassium electrophysiologic buffer (KEB) was prepared similarly, except with 
60 mM KCl and 79 mM NaCl. 
2.2. Embryonic Stem Cell Culture and Neuronal Differentiation 
Murine embryonic stem cells were maintained and differentiated into ESNs as described [28]. ESNs 
were plated in PDL-coated 60 mm dishes at 125,000 cells/cm
2 or PDL- and laminin-coated 18 mm 
coverslips at 100,000 cells/cm
2 and maintained in Neurobasal-A medium (NBA) with B27 vitamins 
(Invitrogen, Carlsbad, CA, USA). 
2.3. Immunoblotting 
ESN cultures were washed with 2 mL PBS, lysed by addition of 250 µL of denaturing cell lysis 
buffer (Sigma-Aldrich) and harvested by scraping. Lysates were vortexed briefly, stored at 4 ° C for  
30 min and clarified by centrifugation for 5 min through a Qiashredder (Qiagen, Valencia, CA, USA) Toxins 2011, 3                                       
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at  16,000  xg.  Total  protein  concentration  was  determined  by  bicinchoninic  acid  (BCA)  analysis 
(Thermo Scientific, Rockford, IL, USA), and 15 μg of total protein was separated on a 12% Nupage 
gel (Invitrogen) with MOPS running buffer. Gels were transferred to PVDF and probed with a mouse 
anti-SNAP-25  antibody  (Abcam,  Cambridge,  MA,  USA)  and  a  mouse  anti-syntaxin-1a  antibody 
(Abcam), both diluted 1:1000 in TBS Superblock with 0.05% Tween-20 (TBST, Invitrogen). Bands 
were visualized with goat anti-mouse Alexa-488 diluted 1:2500 in TBST and imaged with a Versadoc 
MP4000 (Biorad, Hercules, CA, USA). 
2.4. Time-Lapse Confocal Microscopy 
Images  were  collected  on  a  Zeiss  LSM-700  confocal  microscope  with  constant-temperature 
environmental chamber.  For Fluo-4 staining, ESNs on 18-mm coverslips were loaded with  1  μM  
Fluo-4  for  20  min  and washed  thoroughly.  Coverslips  were  mounted  in  a  Warner  (Hamden,  CT) 
closed-bath imaging chamber, maintained at 37 ° C with a heated stage and perfused with phenol-free 
Hibernate (Brainbits, Springfield, IL). For calcein green staining, cells were incubated with 1 µM 
calcein  green in NBA for 30 min, then washed thoroughly and mounted as above.  In both cases, 
coverslips were imaged at 63×  using the 488 laser and manufacturer recommended filter sets.  
3. Results and Discussion 
3.1. Results 
3.1.1. Optimization of the Screening Model 
Previously we reported that 0.81 pM BoNT/A treatment for 24 h results in cleavage of 50% of 
SNAP-25  in  ESNs  [28].  Reasoning  that  application  of  higher  doses  for  a  shorter  period  might 
accelerate  toxin  internalization,  we  exposed  ESNs  to  0.67–670  pM  BoNT/A  for  3  h  or  6  h  and 
evaluated SNAP-25 cleavage after 24 h (Figure 1A). In comparing the percent cleaved SNAP-25 at  
24  h  following  either  3  or  24  h  intoxication,  we  found  that  roughly  three-quarters  of  toxin 
internalization occurs within the first few hours. Since both 6.7 and 67 pM produced roughly 50% 
cleaved  SNAP-25  after  3  h  exposure,  we  longitudinally  evaluated  BoNT/A  activity  from  3–96  h 
(Figure 1B). At each concentration the rate of SNAP-25 cleavage per hour slowed dramatically after 
24 h, suggesting a balance between rates of SNAP-25 synthesis and cleavage (Figure 1C). Based on 
these data, we designed a screening assay in which ESNs were exposed to 6.7 pM BoNT/A for 3 h, 
then washed and incubated for 21 h to allow full toxin activation. Candidate therapeutics were applied 
at  24  h,  and  the  recovery  of  full-length  SNAP-25  was  evaluated  48  h  after  therapeutic  treatment 
(summarized in Figure 1D). The duration of incubation following treatment was selected based on 
reports that approximately 2% of cellular SNAP-25 is recycled per hour [30]. 
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Figure  1.  Kinetics  of  SNAP-25  cleavage  following  internalization  of  BoNT/A  under 
different conditions. (A) DIV 25-31 ESNs in 6 cm dishes were treated with 0.67–670 pM 
BoNT/A in B27-NBA medium for 3 h (white columns) or 24 h (gray columns). For the 3 h 
treatment,  cells  were  washed  twice  to  remove  toxin  at  3  h  and  incubated  for  an  
additional 21 h. All treatments were harvested at 24 h and the percent of cleaved SNAP25 
was determined by densitometry of western blots; (B) Summary of SNAP-25 cleavage in 
embryonic stem cell-derived neurons (ESNs) between 24 to 96 h after a 3 h exposure to 6.7 
or  67  pM  BoNT/A;  (C)  Evaluation  of  the  rate  of  SNAP-25  cleavage,  measured  as  
percent-cleaved SNAP-25 per hour, averaged across each time point. For all experiments,  
n = 5 or more replicates; (D) Drug discovery treatment paradigm designed around kinetics 
of BoNT/A internalization and SNAP-25 cleavage in ESNs. 
 
3.1.2. LTX Treatment of BoNT/A-Treated ESNs Restores Full-Length SNAP-25 Protein within 48 h.  
To  evaluate  whether  LTX  treatment  altered  light  chain  (LC)/A  activity  in  ESNs,  
BoNT/A-intoxicated ESNs were exposed to 400 pM LTX for 6.5 or 13 min, and SNAP-25 integrity 
was evaluated after 48 h. As a control, ESNs were also treated with 60 mM K
+ (KEB) for 1.5 min, 
which evokes Ca
2+-dependent glutamate release [28]. LTX treatment resulted in rescue of 92 ±  4.6% 
and 98 ±  1.7% (6.5 and 13 min, respectively) of full-length SNAP-25 within 48 h, whereas KEB 
treatment  showed  no  difference  from  untreated  neurons  (Figure  2).  The  restoration  of  uncleaved 
SNAP-25 indicates that some aspect of LTX treatment results in the inactivation or clearance of LC/A 
from synaptic termini. Furthermore, these data suggest that latrotoxin may be the active moiety in 
experiments  demonstrating  that  the  administration  of  crude  homogenate  from  black  widow  spider 
venom glands to BoNT/A-paralyzed neuromuscular junctions dramatically accelerates recovery [25]. Toxins 2011, 3                                       
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Figure  2.  LTX  but  not  K
+  rescues  SNAP-25  expression  within  48  h  in  
BoNT/A-intoxicated ESNs. BoNT/A-intoxicated ESNs were treated with 60 mM K
+ or 400 
pM  LTX  for  designated  times,  and  SNAP-25  cleavage  was  evaluated  after  48  h  by 
densitometry of western blots. Syntaxin is shown as a loading control. 
 
3.1.3. LTX Treatment Results in Prolonged Ca
2+ Internalization 
LTX treatment incurs fulminant neurotransmitter release from primary neurons, partly in response 
to profound levels of Ca
2+ internalization [31]. Since LTX treatment resulted in recovery of full-length 
SNAP-25 in ESNs, whereas KEB did not, we used the fluorescent intracellular calcium sensor Fluo-4 
to  compare  the  amplitude  and  duration  of  Ca
2+  internalization  evoked  by  these  two  treatments.  
Time-lapse  confocal  microscopy  analysis  of  DIV  21  ESNs  treated  with  KEB  demonstrated  an 
immediate rise in Fluo-4 fluorescence (Figure 3A). Fluorescence intensity increased within 15 s of 
KEB treatment, remained high for about 90 s and subsided prior to washout at 2.5 min (Figure 3B). 
Conversely, while ESNs treated with 400 pM LTX also showed a strong rise in Fluo-4 fluorescence, 
there were several key differences in the kinetics of the Ca
2+ response. First, there was a 1.5 min delay 
between LTX addition and the onset of Fluo-4 fluorescence, suggesting that spider toxin requires time 
to bind synaptic receptors and form pores within the membrane at this concentration (Figure 3B). Unlike 
the  self-limiting  response  from  KEB  treatment,  LTX  induced  a  steady  increase  in  Fluo-4  signal 
throughout the experiment, even following rinses to remove residual toxin, demonstrating that LTX 
results in loss of cellular ionic homeostasis and that the KEB response was not limited by reduced levels 
of extracellular Ca
2+. No apparent differences in onset, amplitude or duration were noted within the  
20 min experimental window between the 6.5- and 13 min LTX treatment, nor did a 24 h intoxication 
with 67 pM BoNT/A prior to LTX or KEB treatment affect Ca
2+ internalization (not shown). 
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Figure  3.  Kinetics  of  acute  Ca
2+  influx  mediated  by  treatment  with  LTX  or  K
+.  
(A) Increased Ca
2+ influx (Fluo-4; green) peaked rapidly in response to 60 mM K
+ and 
returned to basal levels within 120 s (upper panels); 6.5 min treatment with 400 pM of 
LTX  resulted  in  rapid  increase  of  Ca
2+ with  sustained  intensity  for  over  570  s  (lower 
panels); (B) Quantitative summary of Ca
2+ response following addition (down arrows) of 
60  mM  K
+  (closed  diamonds;  dashed  arrows)  or  400  pM  LTX  (open  diamonds;  solid 
arrows) from a single field of view. Whereas the K
+-induced Ca
2+ response returned to 
basal levels prior to washout (up arrows), the LTX-induced Ca
2+ response continued to 
increase through 570 s. Scale bar = 10 µm. 
 
3.1.4. LTX-Treated ESNs Exhibit Evidence of Excitotoxicity That Partially Resolves between 24–48 h 
Differential interference contrast images captured 15 h after treatment indicate that cultures treated 
with LTX for 6.5 min have large numbers of distributed varicosities and disrupted processes, whereas 
cultures treated with KEB for 13 min do not (Figure 4A). LTX treatment of ESNs decreased the total 
protein yield following cell lysis by 44 ±  16% and 52 ±  19% (6.5 and 13 min, respectively) compared 
to controls at 48 h after treatment (p < 0.01, n = 6; Figure 4B).  We used calcein green staining to 
compare morphological changes in ESNs during the emergent and long-term response to LTX versus 
KEB. These observations are in agreement with results from LTX-treated spinal cord motoneurons and 
cerebellar granule neurons [31]. The development of axodendritic varicosities from existing processes 
was apparent within 30 min of LTX addition (Figure 5). Although neurons remained viable 24 h and 
48 h after treatment, there was an overall decrease in viability and persistent evidence of varicosities. 
By 48 h some of these varicosities were resolved, suggesting that neuronal regeneration was underway. Toxins 2011, 3                                       
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Figure  4.  Comparison  of  neuronal  morphology  changes  and  total  protein  yield  after 
treatment with K
+ or LTX. (A) DIV 22 ESNs were treated with either 60 mM K
+ (top) or  
400 pM LTX in BEB (bottom), then perfused for 30 s with BEB. Differential interference 
contrast images were taken of the same field at the indicated time points. Scale bar = 10 µ m; 
(B) Total protein yield (see methods) from cultures (n = 3) treated with 400 pM LTX for  
6.5 or 13 min was decreased by approximately 50% relative to untreated cultures.  
 
Figure  5.  Examination  of  varicosity  formation  in  calcein-labeled  ESNs  over  time.  
(A). Top panels, low magnification image; bottom panels, high magnification of boxed 
area in upper panel. Arrows identify representative varicosities that appeared within 24 h 
and showed a substantive decrease in area by 48 h after treatment; (B) Varicosities appear 
as soon as 22 min after addition of LTX. All images were of the same field of view for all 
time points. Scale bar for all images = 10 µm. 
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Figure 5. Cont. 
 
3.2. Discussion 
3.2.1. Considerations in Developing a Screening Methodology 
Although we previously demonstrated that neurons derived from embryonic stem cells have the 
potential of acting as  a biologically relevant platform for botulinum research, we did not develop 
screening  protocols  to  maximize  the  likelihood  of  rapidly  identifying  therapeutically  useful  
candidates [28]. In this work we started by developing a cell-based assay using the kinetics of BoNT/A 
internalization and activation in ESNs to standardize the evaluation of therapeutic candidates. 
Although it is a widespread practice to use toxin concentrations that are several orders of magnitude 
above the EC50 followed immediately by therapeutic administrations to expedite therapeutic screening 
assays, for several reasons this approach significantly increases the risk of failing to identify a valid 
therapeutic [32–35]. First, internalization of BoNT at high concentrations may result in broad cellular 
distribution as opposed to synaptic localization, altering the ability to evaluate therapeutic efficacy. 
Second, only a fraction of internalized toxin is capable of cleaving the majority of SNAP-25 within 6 h 
(see Figure 1). Thus, evaluating therapeutic candidates before all the internalized toxin is activated will 
artificially increase the ratio between therapeutic molecules and toxin, thereby increasing the apparent 
therapeutic activity. Finally, a therapeutic candidate applied too early may disrupt toxin processing 
rather  than  interfere  with  fully  functional  toxin.  This  latter  point  is  particularly  relevant  in  
high-throughput screening approaches for post-exposure therapeutics in which libraries are selected 
without a mechanistic bias.  
In  consideration  of  these  concerns,  we  designed  an  assay  around  three  principles  intended  to 
mitigate risks and ensure a high level of sensitivity for therapeutic efficacy. First, an incubation step 
was  included  between  the  removal  of  holotoxin  and  prior  to  therapeutic  administration  to  allow 
internalized light chain to become fully activated. This step was designed to be sufficiently long to 
establish  a  steady  state  between  cleavage  of  existing  SNAP-25  and  synthesis  of  new  SNAP-25. 
Second, a dose was selected that would result in approximately 50% cleavage of SNAP-25 within the 
given time frame,  yet be as  low as  possible to encourage toxin  internalization and trafficking  by 
synaptic endocytosis rather than non-specific endocytosis. Third, treatment efficacy timescales were 
selected around presumptive mechanisms of action. Thus, using dose response curves at multiple time 
points and exposure durations, we identified a 3 h exposure to 6.7 pM, with therapeutic application  
at 24 h and SNAP-25 evaluation at 72 h as the preferred model. 
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3.2.2. LTX Rescue of Full-Length SNAP-25 Expression 
The  finding  that  LTX  treatment  of  BoNT/A-intoxicated  ESNs  rescued  full-length  SNAP-25 
expression is the first instance of a successful therapeutic application in derived neurons. This finding 
resulted  from  the  inactivation  of  LC/A  by  an  unknown  mechanism,  allowing  newly  synthesized 
SNAP-25 to accumulate without being proteolytically cleaved by LC/A. It should be noted that we 
have  not  yet  evaluated  the  functional  rescue  of  synaptic  signaling  or  the  regeneration  of  normal 
synaptic morphologies with appropriate localization of synaptic proteins. The significant decrease in 
total protein recovered argues that some degree of neurotoxicity has occurred, and this is corroborated 
by morphological changes. It may be that most of the existing synapses have been disrupted in such a 
fashion  to  inactivate  LC/A,  or  that  the  LC/A-intoxicated  synapses  are  more  sensitive  to  
LTX-treatment.  The  data  does  suggest  that  LTX  treatment  results  in  calcium  ‗overload‘  and  the 
abnormal flux of other ions through non-selective, cationic pores in the synaptic membrane, any of 
which may prove injurious to neurons [31,36]. The profound and sustained increase in cytosolic Ca
2+ 
observed  in  ESNs  followed  by  acute  evidence  of  axodendritic  varicosities  is  characteristic  of 
excitotoxicity and presents a possible mechanism for clearance or inactivation of LC/A from synaptic 
termini via synaptic degeneration. Whether such degeneration results in the physical loss of LC/A from 
the  synaptic  compartment  or  in  accelerated  degradation  of  synapse-localized  proteins  via  cellular 
proteosomal clearance mechanisms is unknown, but clearly of interest. Another possibility is that the 
significant  increase  in  intracellular  Ca
2+  more  directly  inhibits  the  BoNT/A  light  chain  cannot  be 
discounted based on these data; e.g., through induction of autocatalysis [37].  
3.2.3. Is Neuronal Degeneration and/or Excitotoxicity Responsible for the Loss of BoNT Persistence? 
Recovery  from  botulinum  requires  the  re-innervation  of  the  inactive  muscle  fiber,  whether  by 
regeneration of the original  endplate or  by  establishment  of a new endplate via axonal  sprouting.  
In  vivo,  it  appears  that  the  endplate  disassembles  and  the  presynaptic  compartment  regresses  in 
response to BoNT intoxication [38]. Shortly afterward, new axonal sprouts develop and attempt to  
re-innervate the target muscle fiber. The original endplate is eventually regenerated once the light 
chain has been cleared from the presynaptic terminal and appears to regain control as the primary 
efferent to the muscle fiber. The coordination of these events demonstrates the importance of synaptic 
remodeling in  recovery  of normal  synaptic function after intoxication.  It  may be possible that  by 
disrupting  the  integrity  of  the  original  synaptic  terminal,  BoNT  light  chains  no  longer  remain 
associated with intoxicated synapses, thereby enabling the immediate re-innervation of endplates by 
re-activated nerve terminals. Similarly,  in  vivo  studies  have demonstrated dramatically  accelerated 
recovery from paralysis following BoNT intoxication following nerve crush injury  [26,27].  If this 
general  approach  proves  to  be  efficacious  in  facilitating  recovery  from  intoxication  in  vivo,  then 
induced  regeneration  of  paralyzed  synapses  could  offer  a  novel,  serotype-independent  therapy  for 
intoxication by persistent BoNTs. 
The formation of varicosities in response to  LTX treatment is suggestive of the morphological 
changes  described  following  application  of  excitotoxic  stimuli  to  cultured  neurons.  For  example, 
glutamate  treatment  leads  to  varicosity  formation  in  glutamatergic  dendrites,  whereas  veratridine Toxins 2011, 3                                       
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inactivation of voltage-gated sodium channels causes varicosity formation in both axons and dendrites. 
Under conditions of a sublethal excitotoxic stimulus, these varicosities have proven to be reversible via 
volume recovery pathways, although it is not known if axons and dendrites utilize similar mechanisms 
to  resolve  neuronal  swelling  [39–41].  While  the  nature  of  the  potential  relationship  between 
excitotoxicity resolution and loss of BoNT persistence is still unclear, these results indicate that ESNs 
provide  a  stable  cell-based  platform  to  further  interrogate  the  effect  of  LTX-induced  synaptic 
regeneration on BoNT-persistence in cultured neurons.  
3.2.4. ESNs Provide a Responsive, Genetically Tractable Model for LTX Research 
There  are  several  aspects  of  LTX  activity  that  are  not  well  understood  [10].  For  example,  in 
addition to the formation of cation-selective pores permeable for Ca
2+, LTX mutants incapable of 
forming pores can still induce membrane depolarization through inhibition of voltage-gated potassium 
channels and activation of L-type Ca
2+ channels [42,43]. Whereas synaptic exocytosis induced by this 
mode of LTX action is dependent on the presence of the classical SNARE machinery, there is evidence 
that substantial levels of neurotransmitter release induced by pore-mediated Ca
2+ internalization can 
still occur despite the absence of SNAP-25, VAMP-2 or Munc-13 [16]. Whether this involves a novel 
complex that can effect exocytosis at high Ca
2+ concentrations or has a more mundane explanation 
such as enhanced reversal of membrane-associated amino acid transporters in response to changes in 
cytoplasmic  ion  concentrations  or  ATP-depletion  is  not  known  [44,45].  However,  here  we  have 
demonstrated  that  ESNs  offer  an  LTX-sensitive,  neuron-based  platform  that  has  the  potential  to 
replace  the  use  of  primary  neurons  and  neurogenic  cells  in  studying  the  molecular,  cellular  and 
functional consequences of intoxication by LTX. As we have previously described for BoNTs, the 
additional capabilities of genetic tractability, neuronal subtype homogeneity and lot-to-lot consistency 
mean that the ESN model may also be a transformative tool for LTX research [46]. 
4. Conclusions 
The  finding  that  LTX  treatment  of  BoNT/A-intoxicated  ESNs  rescued  full-length  SNAP-25 
expression  is  the  first  demonstration  of  a  successful  therapeutic  application  in  derived  neurons. 
Although LTX treatment may not be a viable clinical therapy due to its broad activity, these data 
demonstrate  that  the  general  approach  of  induced  synaptic  degeneration  may  accelerate  neuronal 
recovery from BoNT intoxication. Furthermore, they also suggest that LTX may be the active moiety 
in demonstrations that injection of paralyzed EDL muscles with crude homogenates from black widow 
spider venom glands facilitates recovery of muscle tension [25]. Finally, this work demonstrates that 
ESNs are a valid research tool for study of the mode of action of multiple neurotoxins, and thus may 
provide a transformation research platform for neurotoxin research and drug discovery. 
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